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Posttransplant lymphoproliferative disorder (PTLD) is a potentially fatal complication of solid organ transplantation. Themajority
of PTLD is of B-cell origin, and 90% are associated with the Epstein-Barr virus (EBV). Lymphomatoid granulomatosis (LG)
is a rare, EBV-associated systemic angiodestructive lymphoproliferative disorder, which has rarely been described in patients
with renal transplantation. We report the case of a patient with renal transplantation for SLE, who presented, 9 months after
renal transplantation, an EBV-associated LG limited to the intracranial structures that recovered completely after adjustment of
her immunosuppressive treatment. Nine years later, she developed a second PTLD disorder with central nervous system initial
manifestation. Workup revealed an EBV-positive PTLD Burkitt lymphoma, widely disseminated in most organs. In summary,
the reported patient presented two lymphoproliferative disorders (LG and Burkitt’s lymphoma), both with initial neurological
manifestation, at 9 years interval. With careful reduction of the immunosuppression after the first manifestation and with the
use of chemotherapy combined with radiotherapy after the second manifestation, our patient showed complete disappearance
of neurologic symptoms and she is clinically well with good kidney function. No recurrence has been observed by radiological
imaging until now.
1. Introduction
Posttransplant lymphoproliferative disorders (PTLDs) in-
clude a heterogenous group of lymphoid proliferation oc-
curring in recipients of bone marrow and solid organ
transplants associated with immunosuppressive drug admin-
istration. Transplant patients undergoing long-term and
heavy immunosuppressive treatments display a higher risk
of developing lymphomas than the general population. The
incidence of PTLD is estimated to vary from 2% in renal
transplant recipients to 5–9% in heart recipients [1]. Most
are B cell in origin and associated with the Epstein-Barr
virus (EBV). A manifestation in the CNS is documented in
less than 10% of all EBV + PTLD cases. We report here the
followup of a patient with lymphomatoid granulomatosis
after renal transplantation [2] who developed PTLD Burkitt
lymphoma 9 years later, both times presenting with neuro-
logical symptoms.
2. Case Report
The patient was diagnosed in 1977, at the age of 16, with
systemic lupus erythematosus (SLE). In 1998 she underwent
a renal transplantation for end-stage renal failure. The donor
was Epstein-Barr virus (EBV) positive (IgG VCA IF positive,
EBNA AC IF positive, IgM VCA IF negative), whereas
the patient was EBV negative. Immediate posttransplant
evolution was characterized by two acute rejection episodes,
treated with methylprednisolone (500mg i.v. twice daily),
and a stenosis of the transplanted ureter, which needed
surgical correction. The patient’s therapy regimen included
Cyclosporin A 200mg p.o. twice daily, mycophenolate
mofetil (MMF) 600mg/m2 p.o. twice daily, and prednisone
30mg p.o. daily. In the following months the patient devel-
oped an abducens nerve palsy, a peripheral facial nerve palsy
with ageusia, a trigeminal hypesthesia, and a herpes zoster
of T10-11 dermatomes, all on the left side. A cranial MRI in
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January 1999 showed a right frontal gadolinium enhancing
lesion, and a lumbar puncture revealed lymphocytic pleocy-
tosis (white blood cell count of 43/mm3 from which 90.5%
lymphocytes, 0.5% plasmocytes, and 8.5% monocytes, CSF
glucose count of 8mmol/L , and total protein concentration
of 1380mg/L). The patient was still seronegative for EBV,
but cerebrospinal fluid polymerase chain reaction (PCR) was
positive for EBV. Meanwhile she complained for the first
time of posterior chest pain. Chest X-ray was normal, but
a CT scan showed a localized thickening of the pleura. The
pleura biopsy showed multiple foci of severe inflammatory
reaction with a mixed cell type, including lymphocytes,
plasma cells, macrophages, and giant cells. Numerous blood
vessels presented extensive vasculitis. Immunohistochem-
istry showed the inflammation to be made up of small T
cells (CD3+) surrounded by foci of rare B cells (CD20+,
IgG+) without any morphological criteria of malignancy. A
rearrangement study for the T-cell receptor (TCR) gene (T
cells), as well as search for clonal rearrangement of the IgH
chain gene (B cells) by southern blot, failed to reveal any
monoclonality. In situ hybridization for EBV (EBER 1/2) in
the pleural biopsy material was negative. This histological
picture of a polymorphous and granulomatous type of
inflammatory reaction centered around vessels with nerve
involvement, necrosis, and various numbers of large atypical
cells was highly suggestive for the diagnosis of lymphomatoid
granulomatosis [2]. Cyclosporin A and MMF were tapered
by 50% and prednisone increased up to 60mg daily per
os for about one month. MMF was then stopped and
prednisone gradually decreased. The neurological symptoms
resolved over several months. Eight years later the patient
still has a functioning renal graft, on prednisone 5mg
per day and Cyclosporin A 100mg twice daily p.o.. The
patient seroconverted for EBV (IgG VCA positive by IF,
EBNA AC IF negative, IgM VCA IF negative) more than
a year after transplantation, once immunosuppression was
minimal, without clinical symptoms.
In November 2008, the patient developed diplopia and
left palpebral ptosis. A complete left III palsy with ptosis
and mydriasis, a mild left peripheral facial nerve palsy with
ageusia, and hypoesthesia in the first branch of the left
trigeminal nerve were found. The corrected visual acuity
was 0.8 in the left and 1.0 in the right eye. There were no
meningeal signs. There was slight conjunctival injection but
no exophtalmos. The patient had symmetrical hyperreflexia
without other corticospinal signs.
Cranial CT showed a contrast enhancing mass of
20 × 20 × 13mm invading the left sella turcica (Figure 1),
confirmed by an MRI. Complete blood count and peripheral
smear were normal. Lumbar puncture revealed normal
cell count (1 cell), mild increased protein concentration
(393mg/L), and normal glucose level (3.1mmol/L). PCR
studies performed on the peripheral blood and in the CSF
were negative for cytomegalovirus (CMV), herpes virus
simplex (HSV), and toxoplasmosis but demonstrated an EBV
viral load of 155 900 copies/mL. Serum HIV test was nega-
tive. The hypophyseal hormones (LH, FSH, prolactin) were
in the normal range. The positron emission tomography-
computed tomography (PET-CT) showed a widespread
Figure 1: Cranial computed tomography shows amass of 20× 20×
13 mm in the left part of the sella turcica.
Figure 2: The positron emission tomography-computed tomogra-
phy (PET-CT) shows a widespread pathological uptake of radio-
tracer (F-FDG), including bones, kidneys, and an intraperitoneal
pelvic mass.
disease (Figure 2). A transphenoidal biopsy of the mass
showed a high-grade B Lymphoma of the Burkitt type
(Figures 3 and 4) with a majority of medium-size cells
with moderate cellular pleomorphism and variable nucleolar
prominence.Mitosis andmacrophages with apoptotic bodies
were numerous. The immunohistochemical profile of these
cells was CD20+ and CD79a+ with a coexpression of
CD10 and Bcl6. The proliferation rate (Ki67) was 100%.
A t(8; 14) translocation was detected by fluorescent in
situ hybridization (FISH) analysis. The pelvic bone marrow
aspiration showed no signs of medullary infiltration from the
lymphoma. EBV was not searched in the tumor or in the
bone marrow.
After diagnosis of PTLD Burkitt lymphoma, the
immunosuppression was reduced and an intravenous
chemotherapy associating Rituximab/CHOP (8 cycles), and
an intermediate dose of Methotrexate (1.5mg/m2), adapted
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Figure 3: Tumor cells of large size admixed with numerous macrophages containing apoptotic bodies (“starry sky” aspect).
(a) (b)
Figure 4: The proliferation rate (Ki67/MIB1) is 100% (a). The tumor cells expressed B lymphoid markers (not shown) with a coexpression
of CD10 (b).
to the renal function (5 cycles), was administrated. Vin-
cristine had to be stopped because of new polyneuropathy,
and cyclophosphamide was reduced by 25% after 5 cycles
because of haematological toxicity. PET-CT after the end of
chemotherapy was normalized except a small FDG-uptake in
the ethmoid and sphenoid sinuses. Local radiation therapy
was performed. The patient’s neurological signs disappeared
except for a mild residual facial palsy.
3. Discussion
Our patient with history of renal transplantation for SLE pre-
sented with two lymphoproliferative disorders, LG followed
by Burkitt’s lymphoma, both associated with EBV, at 9 years
interval.
PTLD is one of the most important complications of
organ transplantation, comprising 15% of all neoplasms
[3], and long-term prognosis can be improved with early
recognition and appropriate therapy. Despite numerous
therapeutic advances, mortality rate reaches up to 60% in
some reports. PTLDs usually have rapid onset, aggressive
behavior, and are located extranodally. The exact relationship
between lymphomatoid granulomatosis (LG) and posttrans-
plant lymphoproliferative disorders (PTLDs) is not clear.
Both are observed in immunodeficient patients and are
Epstein-Barr virus driven [4]. Chronic EBV infection is
probably themost important single event in the development
of PTLD and LG, through activation of proto-oncogenes
or surviving genes. EBV is associated with high proportion
(89%) of posttransplant B-cell PTLD [5] and has been
shown to promote B-cell proliferation by expressing an
EBV-transforming protein (latent membrane protein 1)
that engages the tumor necrosis factor receptor signal-
transduction pathway to activate important regulators of
cell growth, diﬀerentiation, or survival, such as nuclear
factor kappa B and mitogen-activated protein kinases [4].
In particular, pretransplant EBV seronegativity followed
by posttransplant seroconversion has been shown to be a
major contributing risk factor for developing PTLD [6–8].
Monitoring the viral loads during the treatment may aid
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management because persistently elevated titers necessitate
alternative treatment [9].
Although the association between EBV and PTLD is
well established, the presence of EBV in tumor cells is not
required for the diagnosis of PTLD. Negative findings in the
biopsy material may reflect technical problems in retrieving
the EBV genome from the rather rare infected B cells. This
implies that, according to the international classification, any
lymphoma arising in a posttransplant patient is considered
to be a (variant of) PTLD [10]. Monitoring blood EBV load
may detect early PTLD but cannot be used as a reliably
early marker for PTLD. Assays are not standardized, and it
is not known which tissue should be sampled or when to
be tested. However, it is important to diﬀerentiate Burkitt-
type PTLD from other types when deciding upon a course
of treatment. Burkitt’s lymphoma is not likely to be aﬀected
by a reduction in immunosuppression and characteristically
requires adjuvant chemotherapy or radiation [11]. More
eﬀective treatment approaches to this disorder therefore need
to be developed.
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